Skip to main navigation Skip to search Skip to main content

A Phase 2 Randomized, Double-Blinded (BMS-562247 and enoxaparin), Active controlled (enoxaparin and wafarinJ), Parallel-Arm, Dose-Response Study of The Oral Factor Xa

Project: Research

Project Details

StatusFinished
Effective start/end date12/15/04 → 12/14/06

Funding

  • Bristol Myers Squibb Company: $14,683.00